Navigation Links
Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/8/2007

matory diseases, such as rheumatoid arthritis and inflammatory bowel disease, due to their ability to down-regulate inflammatory cytokines such as TNF alpha.

RDEA119, Ardea's lead compound from this program, is a potent, non-ATP competitive, highly selective inhibitor of MEK. Ardea plans to initiate a Phase 1 clinical trial evaluating RDEA119 in advanced cancer patients in the second half of 2007. Preclinical data suggest that RDEA119 may have favorable pharmaceutical properties, including the potential for convenient oral dosing and limited retention in the brain, which, in turn, may result in a reduced risk of CNS side effects. Beyond RDEA119, the Company is evaluating a broad range of MEK inhibitors from several distinct chemical classes and plans to bring forward one of these compounds into a first-in-human study in the fourth quarter of this year.

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forw
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 Touro College has announced ... CanniCare,s application for one of five media marijuana licenses to ... Dept. of Health (DOH).  If CanniCare ... medicinal cannabis.  "Our college is supportive of ... president of the Touro College System. "There is still a ...
(Date:7/29/2015)... , July 29, 2015  AcelRx Pharmaceuticals, ... company focused on the development and commercialization of ... breakthrough pain, today announced that it will release ... Monday, Aug 3rd, 2015. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on Aug 3rd, ...
(Date:7/29/2015)... 29, 2015   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 financial results will be released on Thursday, August ... conference call and live webcast at 1:30 p.m. PT ...
Breaking Medicine Technology:Touro College Announces Support for CanniCare's Medical Cannabis License Application 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4BioLife Solutions to Report Second Quarter 2015 Financial Results and Provide Business Update on August 6, 2015 2
... Feb. 24, 2012  Mylan Inc. (Nasdaq: MYL ... North America and the company,s Mylan Pharmaceuticals subsidiary, has ... Pharmaceutical Association,s (GPhA) board of directors. GPhA is an ... and suppliers. Mauro,s election to this role further supports ...
...  With fewer products in the pipeline and more at ... the commercial life of mature brands are critical to ... add as many as 10 years and billions of ... brand. To help biopharmaceutical companies more ...
Cached Medicine Technology:Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA 2Report Delivers ROI Analysis on Key Lifecycle Management Strategies Utilized by the Pharmaceutical Industry 2
(Date:7/29/2015)... ... July 29, 2015 , ... Ticket Down is a reliable source of authentic ... USA . , The international soccer schedule of matches played on American soil ... September 8th, one of the world’s greatest teams, Brazil, will travel to North America ...
(Date:7/29/2015)... ... July 29, 2015 , ... This year, the threat of flooding is higher ... where there is water, mold is not far behind. Paul Davis, a leading provider ... water and mold damage. Paul Davis is regularly called on to handle these types ...
(Date:7/29/2015)... ... July 29, 2015 , ... San Fernando Valley ... Ultherapy. For a limited time only, patients can get the complete treatment process with ... patients who prefer a non-invasive treatment and have loose or sagging skin. , ...
(Date:7/29/2015)... Los Angeles, CA (PRWEB) , ... July 29, 2015 , ... We are privileged to ... at Keck Medicine of USC as the ninth best ophthalmology hospital in the nation for ... the top 10 American hospitals for ophthalmology. , “It is an honor to be ...
(Date:7/29/2015)... ... ... A June 10, 2015 article from the News-Press, entitled " It's Never Too ... skin cancer screenings from an early age. Skin cancer can strike at any age, ... cancer is rarely fatal; however, if left alone for too long, the fatality rate ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3
... Research Institute have developed a simplified and more effective method ... by clinical pharmacologist Dr. Ross Feldman, showed that more patients ... - when their family doctors used a simplified treatment protocol ... drugs available to treat high blood pressure. While the study,s ...
... -- China Holdings, Inc.,(OTC Bulletin Board: CHHL), ... subsidiaries engage in multiple China-focused business activities,including ... and pharmaceuticals, announced today the Company has ... rights to develop and construct,the 2nd Biomass ...
... NORTHBROOK, Ill., Nov. 5 In 1963, when Karl,Johnson, ... for the National,Institutes of Health instead of taking a ... did he know that his research would lay the ... the,world. With just a quick built laboratory, a few ...
... - Halogen Software Inc., the leading,provider of Web-based ... third quarter of 2007 was the organization,s strongest,to ... category with nearly,50 percent year-over-year revenue growth over ... performance is a high priority for our,organization and ...
... Fla., Nov. 5 JM, a 71 year old ... scale ultrasound,despite a PSA of 7.1. The following year, ... was negative despite adding Color Flow Doppler,Ultrasound. At this ... without a clear path to identify a disease process ...
... ABO-incompatible heart transplantation (heart transplantation among non-compatible ... a year old or younger, researchers reported at ... analysis, based on national data reported to the ... transplanting infant hearts across incompatible blood group is ...
Cached Medicine News:Health News:Changing the way doctors treat high blood pressure 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 3Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 4Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 5Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 6Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 7Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 8Health News:Training Medical Warriors: Tropical Medicine Specialists Who Ward Off Bioterrorist and Global Health Threats Pass the Torch to the Next Generation 2Health News:Training Medical Warriors: Tropical Medicine Specialists Who Ward Off Bioterrorist and Global Health Threats Pass the Torch to the Next Generation 3Health News:Training Medical Warriors: Tropical Medicine Specialists Who Ward Off Bioterrorist and Global Health Threats Pass the Torch to the Next Generation 4Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 2Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 3Health News:New Prostate Cancer Technology Saving Lives 2Health News:New Prostate Cancer Technology Saving Lives 3Health News:Blood-incompatible infant heart transplants safe, may save more lives 2
... A companion product to the new IM3300 ... 300 Watt Xenon Light Source offers some truly ... Source is simply to understand and easy to ... Linvatec has incorporated a new Stand-By Feature, which ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Conducting disposable filter-tips....
Medicine Products: